Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Transgene
  6. News
  7. Summary
    TNG   FR0005175080

TRANSGENE

(TNG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Bioinvent International AB and Transgene Receive IND Approval from the U.S. FDA for BT-001

05/27/2021 | 02:30am EDT

BioInvent International AB and Transgene announced that their Investigational New Drug (IND) application for BT-001 has been granted by the U.S. Food and Drug Administration (FDA). This IND will allow patients in the U.S. to be enrolled into the ongoing Phase 1/2a clinical trial of this novel oncolytic virus BT-001. BT-001 is armed with both a differentiated Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF. The ongoing Phase 1/2a study is a multicenter, open label, dose-escalation trial evaluating BT-001 as a single agent and in combination with pembrolizumab. The Phase 1 part of the trial has already been initiated in Europe, where it is enrolling patients in several countries. BT-001 is expected to elicit a strong and effective antitumoral response by selectively targeting and modulating the tumor microenvironment. In addition, delivering the anti-CTLA4 antibody directly to the tumor aims to induce local Treg depletion and strong therapeutic activity. As a consequence, the safety and tolerability profile of the anti-CTLA4 antibody is expected to be greatly improved due to reduced systemic exposure. BT-001 is being codeveloped through a 50/50 collaboration between BioInvent and Transgene. The Phase 1 trial is divided into two parts. Part A will enroll up to 36 patients with metastatic/advanced solid tumors. Patients will receive single agent, intra-tumoral administrations of BT-001. Part B will explore the combination of intra-tumoral injections of BT-001 with the standard treatment regimen of pembrolizumab in 12 patients. The Phase 2a part of the trial will evaluate BT-001-based combination regimen in several patient cohorts with different tumor types. These expansion cohorts will offer the possibility of exploring the activity of this approach to treat other malignancies not traditionally addressed with this type of treatment.


© S&P Capital IQ 2021
All news about TRANSGENE
09/16TRANSGENE : Gastrointestinal Cancer Drug Study Confirms Potential of Cancer-Kill..
MT
09/16Transgene Presents Data from Phase I Clinical Trial Confirming the Potential ..
CI
09/13GLOBAL MARKETS LIVE : Valneva, Walt Disney, ViacomCBS, General Motors, Amazon...
09/07PRESS RELEASE : CEVEC and UCB sign agreement for the use of CEVEC's ELEVECTA(R) ..
DJ
09/02GLOBAL MARKETS LIVE : Ford, Walmart, Apple, Volkswagen, Tesla...
09/01Transgene Participates in New Cancer Research Consortium
CI
06/28Transgene Announces Update on Phase I Clinical Trial of TG4050
CI
06/25GLOBAL MARKETS LIVE : Facebook, Toshiba, Fedex, Nike, Microsoft...
06/24Transgene announces First Patient Enrolled in Expanded Phase II Clinical Tria..
CI
06/22GLOBAL MARKETS LIVE : Netflix, Boeing, Tesla, Delta Air Lines, Blackstone Resour..
More news
Financials
Sales 2021 11,1 M 13,0 M 13,0 M
Net income 2021 -27,0 M -31,7 M -31,7 M
Net cash 2021 44,7 M 52,4 M 52,4 M
P/E ratio 2021 -8,80x
Yield 2021 -
Capitalization 241 M 282 M 282 M
EV / Sales 2021 17,6x
EV / Sales 2022 28,1x
Nbr of Employees 139
Free-Float 51,4%
Chart TRANSGENE
Duration : Period :
Transgene Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TRANSGENE
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 2,47 €
Average target price 3,80 €
Spread / Average Target 54,2%
EPS Revisions
Managers and Directors
Hedi Ben Brahim Chairman & Chief Executive Officer
Jean-Philippe Del Chief Financial Officer
Eric Quéméneur Chief Scientific Officer & Executive VP
Hemanshu Shah VP-Medical Affairs & International Development
Maud Brandely VP-Clinical Operations & Regulatory Affairs
Sector and Competitors
1st jan.Capi. (M$)
TRANSGENE54.73%292
GILEAD SCIENCES, INC.22.91%89 785
BIONTECH SE340.60%86 750
REGENERON PHARMACEUTICALS34.93%67 775
WUXI APPTEC CO., LTD.35.75%60 418
VERTEX PHARMACEUTICALS-20.33%48 850